News | May 05, 2025
Biocon Biologics secures strong market coverage for Yesintek in US
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
Nadda noted that TB treatment coverage in India has increased from 59% to 85%
These appointments align with the group’s philosophy of having a strong and independent board with exceptional industry experts, ensuring strategic guidance and effective governance
There are 38.4 million people with diabetes in the United States
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore
PROVIGIL and NUVIGIL are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy
Subscribe To Our Newsletter & Stay Updated
